Cat. No. | Product name | CAS No. |
DC1029 |
AZD-1152-HPQA
Featured
AZD1152-HQPA (Barasertib) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM. |
722544-51-6 |
DC5184 |
Epirubicin HCl (4'-epidoxorubicin)
Featured
Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. |
56390-09-1 |
DC8598 |
PLK1 inhibitor GSK461364
Featured
GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM. |
929095-18-1 |
DC11369 |
SPHINX31
Featured
SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50 = 5.9 nM). |
1818389-84-2 |
DC27001 |
SR-4835
Featured
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13. |
2387704-62-1 |
DC28035 |
TCMDC-135051
TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM). |
|
DC28079 |
RPR121056
RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE. |
181467-56-1 |
DC28171 |
Rifalazil
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB). |
129791-92-0 |
DC28185 |
Chloroquinoxaline sulfonamide
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle. Antitumor activity. |
97919-22-7 |
DC28264 |
TC-Mps1-12
TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor, with an IC50 of 6.4 nM. |
1206170-62-8 |
DC28292 |
Cdk1/2 Inhibitor III
Featured
Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B. |
443798-55-8 |
DC28404 |
Caracemide
Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity. |
81424-67-1 |
DC28439 |
Sorivudine
Sorivudine (BV-araU) is an orally active synthetic pyrimidine nucleoside antimetabolite drug. Sorivudine derives its antiviral activity from selective conversion by a specific thymidine kinase present in certain DNA viruses to nucleotides, which can in turn interfere with viral DNA synthesis. |
77181-69-2 |
DC28452 |
(2S,3R)-Voruciclib
(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor. |
1253731-24-6 |
DC28498 |
CDK ligand for PROTAC
CDK ligand for PROTAC is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. |
|
DC28499 |
CDK ligand for PROTAC hydrochloride
CDK ligand for PROTAC hydrochloride is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. |
|
DC28501 |
AMG PERK 44
AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC50 of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC50=7300 nM) and B-Raf (IC50 >1000 nM), respectively. |
1883548-84-2 |
DC28613 |
CDK9-IN-9
CDK9-IN-9 (example 2) is a potent and selective CDK9 inhibitor with an IC50 of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC50 of 155 nM. CDK9-IN-9 has anti-cancer activity. |
2246956-84-1 |
DC28657 |
Cdc7-IN-3
Cdc7-IN-3 (compound I-A) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. |
1402057-87-7 |
DC28658 |
Cdc7-IN-4
Cdc7-IN-4 (compound I-C) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. |
1402059-21-5 |
DC28659 |
Cdc7-IN-5
Featured
Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. |
1402057-86-6 |
DC28660 |
Cdc7-IN-6
Featured
Cdc7-IN-6 (compound I-D) is a potent Cdc7 kinase inhibitor (IC50=4 nM), extracted from patent WO2019165473A1, compound I- D, has anti-tumor activity. |
1402057-88-8 |